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 Evidence from basic research accredits the therapeutic 
outcome to biological effects. Most research into shock 
waves (SW) has focussed on understanding the mecha-
nisms which result in a mechanosensitive feedback be-
tween the acoustic impulse and the stimulated cells, in-
volving specific transduction pathways and gene expres-
sion. These concepts legitimate the potential role of 
ESWT in regenerative therapy  and in treating other, new 
pathological conditions in which both incisive metabolic 
stimulation and angiogenesis are required, such as skin 
ulcers and ‘difficult’ wounds, osteonecrosis or myocar-
dial ischaemia. Other research looks at further, more ad-
vanced clinical applications for ESWT, such as treating 
pathologies like muscle spasticity from neurological le-
sions and parodontopathies.
 This article aims to give a narrative overview of ESWT 
and its mechanisms of action, and to review the current 
clinical applications of ESWT in musculoskeletal disor-
ders and future potential areas for research.
 Physics and Biology of SW 
 Mechanisms of Action 
 In physical terms, SW are rapid, short and distinct sin-
gle fluctuations of acoustic energy from a positive to a 
negative phase. In the target tissue the induced energy 
converges into ‘the focal area or focal volume’, whose size 
will depend on the nature of the physical therapeutic 
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 Abstract 
 Regenerative therapy is one of the most challenging and in-
triguing branches of modern medicine. Basic research has 
demonstrated the effectiveness of extracorporeal shock-
waves (ESWT) in stimulating biological activities that involve 
intra-cell and cell–matrix interactions. These interactions are 
at the basis of the current clinical applications, and open the 
horizons to new applications in tissue regeneration. It is also 
feasible that shock waves could be used to treat various or-
thopaedic pathologies, removing the need for surgery.  How-
ever, suitable translational studies need to be performed be-
fore ESWT can become a valid alternative to surgery.  
 © 2013 S. Karger AG, Basel 
 Introduction 
 Extracorporeal shock wave therapy (ESWT) for the 
treatment of musculoskeletal diseases is a field that is de-
veloping rapidly and attracting increasing attention. Cur-
rently, ESWT is commonly used to treat many orthopae-
dic disorders such as plantar fasciitis, lateral epicondylitis 
of the elbow, calcific tendinopathies of the shoulder and 
non-union of long bone fractures.
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stimulus, the angle at which it is applied and the induced 
pressure values. The intensity of positive pressure and the 
consequent energy discharged close to the target cause 
the direct effect of the SW. This event is influenced by the 
tissues through which the wave front passes, which can 
trigger phenomena of absorption, reflection, refraction 
and transmission of induced energy  [1] . Tensile forces 
produced by the negative phase lead to the transition of 
water molecules into cavitation bubbles which, as they 
expand, are immediately compressed. This leads to an in-
crease in the temperature of the gas contained in the bub-
ble until it implodes, generating spherical SW and vapor 
microjets called ‘jet streams’  [2] . 
 The relationship between the induced energy and the 
therapeutic efficacy of SW is due to the features of the 
acoustic signal rather the intensity of the pressure. It has 
been recognized that high energy levels can cause irre-
versible alterations to the cell structure  [3] , while in sensi-
tive cells low energy levels induce modifications to the cell 
membrane and functional changes in the cytoplasm or-
ganelles, which ultimately stimulate the nucleus. Conse-
quently, the production of proteins, nitric oxide (NO) 
and specific growth factors (GF) contributes to the activa-
tion of the biological processes  [4, 5] .
 Mechanical Effect and Biological Response: 
The Mechanotransduction of the Impulse 
 The mechanisms that enable tissues to recognize and 
convert the intensity, frequency, amplitude and duration 
of an acoustic signal into a biological reaction are still un-
known. Nevertheless, specific features of reactive cells, 
well known for their mechanosensibility  [6] , activate 
links of identification and transmission of the exogenous 
stimuli in ‘unidirectional units of biological information’. 
They stimulate extracellular matrix (ECM)-binding pro-
teins and the nucleus via the cytoskeleton  [7] .  Physiolog-
ical examples of mechanotransduction are endothelial 
cell homeostasis induced and maintained by shear stress 
 [8] or the reaction of the bone lacuno-canalicular net-
work to tensile, shear and compression forces  [9] . Simi-
larly, experimental in vitro studies have demonstrated 
that, in stimulated cells, SW modify transmembrane flux-
es which regulate redox reactions and, consequently, the 
extracellular signal-regulated kinase (ERK) signal trans-
duction pathway which in turn regulates gene expression 
in the nucleus  [10, 11] . Likewise, actual experimental 
findings underline the reversible structural changes in 
collagen conformation and orientation induced by SW in 
tendon samples  [12] .
 Clinical Applications of SW in Bone and in Soft 
Tissues  
 Focused SW  
 Focused SW are generated by electrohydraulic, elec-
tromagnetic and piezoelectric devices. They concentrate 
the acoustic energy on a well-defined point of the target 
tissue, with varying focal volume, depth of penetration, 
level of energetic flux density (EDF) and total energy ad-
ministered  [1] .  In electrohydraulic tools, a high-voltage 
discharge generates the primary SW that follows the va-
porization of the water enclosed in the applicator. An el-
liptical reflector directs the wave into the focal area. In 
an electromagnetic apparatus, the SW generated by the 
coil are converged by an acoustic lens. Lastly, the defor-
mation of the crystals distributed along the spherical cap 
of the piezoelectric systems generates a series of waves 
which, added together, are concentrated in the target 
area  [2] . 
 The use of focused SW, especially when high energy 
levels are used, requires accurate identification of the area 
to be treated. This allows the most favourable therapeutic 
effect and avoids damage to the surrounding tissue. For 
this purpose, radiographic or ultrasound guidance is nec-
essary. In the treatment of soft tissues, patient feedback is 
usually sufficient. 
 Defocused SW Therapy 
 Some electromagnetic and electrohydraulic genera-
tors convert the acoustic wave into planar or defocused 
(soft-focused) waves, which retain the same physical 
characteristics but deliver the energy to a larger surface 
area. The depth of penetration will obviously be lower 
and, therefore, therapeutic use is limited to superficial le-
sions like cutaneous ulcers  [13] .
 Radial SW Therapy 
 Pneumatic generators produce radial waves, or pres-
sure waves, whose physical properties significantly differ 
from those of focused SW. The linear pressure, the low 
energy values, the relatively low velocity of propagation 
and, above all, the short duration of the rise time differ-
entiate radial waves from focused SW  [14] . In radial SW 
generators, the compressed air strikes a bullet contained 
in a cylinder. At the top of this cylinder is the applicator. 
The energy produced by the pressure wave is highest at 
the skin surface, diverging and weakening as it penetrates 
deeper. 
D
ow
nl
oa
de
d 
by
: 
90
.1
47
.2
8.
2 
- 1
1/
5/
20
13
 1
2:
22
:1
4 
PM
 ESWT in Musculoskeletal Disorders Med Princ Pract
DOI: 10.1159/000355472
3
 Main Therapeutic Applications of Extracorporeal SW 
 Disturbances in Bone Healing  
 Surgery is considered the treatment of choice for de-
layed unions and non-unions of fractures. The use of ex-
tracorporeal SW is still considered a secondary alterna-
tive, although several clinical studies have shown analo-
gous results with respect to surgery  [23, 25] . Experimental 
models of fractures demonstrate that SW promote bone 
repair through a typical biological response characterized 
by the production of GF and bone morphogenetic pro-
teins (BMP). It is hypothesized that the osteoblast prolif-
eration induced by SW affects the upregulation of genes 
involved in skeletal development and osteoblastic lineage 
differentiation  [15] , such as the differentiation of bone 
marrow mesenchymal cells into the osteoblast lineage via 
TGF-β 1  [4, 15] . Furthermore, it is postulated that the ef-
fect of SW on the transduction signal in bone cells is real-
ized by the activation of the cyclin E2/CDK2 complex 
 [16] and ERK and p38 kinase activity  [17] . Finally, SW 
have been reported to have a favourable effect on the col-
onization of bioscaffolds, a precursor of future applica-
tions in tissue engineering  [18] . It has been observed that, 
after SW stimulation, osteoblast-like cells proliferate and 
increase the expression of ALP, osteocalcin, collagen type 
I, and bone proteins involved in de novo bone formation 
(such as BMP2, BMP4 and BMP7). A remarkable feature 
of the stimulated cells is their significant migration into 
scaffolds, whereas untreated cells remain on the surface.
 Interesting areas of research include the possible cor-
relation between the acoustic stimulation and production 
of NO, which is one of the main mediators of the biolog-
ical action of SW and is involved in bone metabolism 
 [19] .  Indeed, it has been postulated that mechanical ex-
ogenous impulses can induce an increase in the non-en-
zymatic production of NO as well as of PGE-2 and PGI-2 
in osteocytes as a consequence of an expected activation 
of the lacuno-canalicular network  [8] . Clinical investiga-
tions seem to confirm this possibility. In a study of pa-
tients treated with ESWT for long bone non-unions, 
Wang et al.  [20] reported significant increases in the sys-
temic concentrations of NO, TGF-β 1 , VEGF and BMP-2 
one month after treatment. Although their study presents 
some limitations due to the low number of patients and 
the lack of controls, it suggests a new approach for man-
aging bone fractures. 
 As various studies show, the healing rate of bone non-
unions seems to depend on the site, the type of fracture, 
previous treatments, the time between the trauma and 
SW treatment, adequate stabilization and immobilization 
of the lesion and the size of the fracture gap  [21, 22] . Ret-
rospective studies show that tibial non-unions heal in 6 
months (80% of cases) after a single administration of SW 
(electrohydraulic generator, 4,000 shocks – 0.40 mJ/
mm 2 ), especially when the fracture is closed and proxi-
mally located and the pseudoarthrosis is hypertrophic 
 [23] . Nevertheless, the validation of clinical outcomes is 
a critical aspect of SW treatment for bone fractures. The 
low rate of non-unions limits the possibilities of perform-
ing controlled studies with an adequate number of 
homog eneous patients. For this reason, the only studies 
currently published are multicentric and retrospective. 
Furthermore, non-unions may have been treated origi-
nally with different methods of osteosynthesis, with or 
without the use of bone grafts. Finally, the ethical impli-
cations of using a control group (that remains untreated) 
must also be considered.
 Despite the multiple and simultaneous variables that 
characterize the non-union of long bones, SW treatment 
is a non-invasive procedure that is appropriate for every 
type of non-union as long as the above-mentioned treat-
ment criteria are respected. To evaluate the effectiveness 
of SW, predictive and probabilistic models of analysis 
have been used. Stojadinovic et al.  [24] demonstrated the 
potential of the bayesian model which simultaneously 
analyses multiple clinical data and incorporates all out-
comes and covariates into a single network. In an analysis 
of 349 consecutive patients treated over a 10-year period, 
the authors evaluated the probability of the presence or 
absence of persistent non-union at 6 months after the first 
SW treatment. They observed that the time from trauma 
to treatment with SW therapy and the anatomic site of the 
fracture had a significant effect on the outcome  [24] . The 
highest probability of healing occurred when treatment 
began between 6 and 11 months after trauma. A retro-
spective, non-randomized cohort study showed a similar 
healing rate (around 73%) in SW therapy versus surgery 
 [23] , and a randomized, double-blind, multicentric clini-
cal trial reported significantly better healing in the SW 
groups between 3 and 6 months, with equivalent results 
between 12 and 24 months  [25] .
 Tendinopathies 
 The most frequent application of SW therapy is in the 
treatment of tendinopathies. The small cellular popula-
tion of tendons (5% of the normal tissue volume) is made 
up of a mixed population of tenocytes and tendon stem 
progenitor cells  [26] . Both tendon cells and the collagen 
structure are potential targets of ESWT, particularly in 
later degenerative phases. However, it is not clear wheth-
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er SW activate tendon cells directly, or whether they reg-
ulate the pathogenetic alteration of the ECM homeostasis 
that occurs in tendinopathies.
 Early in vivo experimental studies showed typical his-
tomorphological patterns characterized by a reversible 
inflammatory reaction (which was mostly dose depen-
dent) in tendon cells treated with SW  [27] . A neovascular 
proliferation at the bone-tendon junction associated with 
the release of proangiogenic regulatory factors [NO syn-
thase (NOS) and VEGF] and proliferating GF (PCNA) 
has also been demonstrated  [28] .  
 In vitro, the dose-dependent effect of SW at low ener-
gies results in a proliferative action and an increase in the 
gene expression of collagen types I and III and TGF-β 1 , 
followed by the production of NO and collagen synthesis 
 [29, 30] .  NO is a highly reactive molecule and, in tendon 
healing, all 3 isoforms of the activating enzyme NOS are 
expressed by fibroblasts. NO enhances ECM synthe-
sis and should be overexpressed in injured as well as in 
overused tendon models  [31] . Nevertheless, NO itself 
may lead to an oxidant status, revealed by high levels of 
malondialdehyde, which is an end product of lipid per-
oxidation  [32] . It has not been clarified whether SW reg-
ulate the levels of NO in tendons toward physiological 
values. The regulatory effect of SW has been observed
in the expression of tenocytic markers such as scleraxis, 
tenomodulin, tenascin-C, and type I and III collagens, as 
well as in interleukin (IL)-6 and MMPS 1 and 13 in cul-
tures of pathologic tenocytes  [33, 34] .
 Though supported by clinical data, the validity, effec-
tiveness and reliability of ESWT in the treatment of ten-
dinopathies do not always meet the criteria of evidence-
based medicine  [35] . This is mainly due to an objective 
difficulty in comparing data from non-homogeneous 
studies, which have adopted various types of SW genera-
tors, with differing energy parameters and treatment 
protocols  [36, 37] . The data published regarding patellar 
tendinopathy are particularly controversial; although 
some studies describe the efficacy of ESWT  [35–37] , oth-
ers report no significant difference between ESWT and 
placebo for inducing angiogenesis and clinical improve-
ment  [38] .  
 New Perspectives in ESWT  
 The modern concept of tissue regeneration is strictly 
related to neoangiogenesis. This is a new interpretation of 
the therapeutic effect and opens up new horizons for the 
use of ESWT, over and above its traditionally orthopaedic 
applications. Potential new applications include spastic-
ity, skin ulcers, myocardial revascularization and vascular 
bone disease.
 Spasticity  
 The mechanism of action of SW on spastic muscles is 
still unknown, but it seems that the sonic impulse of SW 
acts on muscle spasticity differently from normal vibra-
tory stimulation. Previous studies on poststroke upper 
limb spasticity suggest that a single administration of 
low-energy SW results in a significant long-term reduc-
tion in muscle tone  [39] . The hypothesis that SW act spe-
cifically on muscles derives from the observed lack of 
change in peripheral nerve conduction and spinal excit-
ability, and an absence of signs of denervation in the mus-
cles. On a functional level, a decrease in the Ashworth 
scale score has been observed, with a contemporary in-
crease in the range of motion and, for the lower limbs, a 
significant increase in plantar surface area and peak pres-
sure at the pedobarometric evaluation  [40] . In vivo stud-
ies on healthy rats suggest that ESWT can affect the neu-
romuscular junctions, causing degeneration and a reduc-
tion in the number of acetylcholine receptors, which in 
turn induces a significant decrease in the maximum com-
pound muscle action potential  [41] . 
 More recently, in a randomized placebo-controlled 
clinical trial, the effects of radial ESWT on spasticity con-
sequent to cerebral palsy were analysed  [42] . The positive 
results (a decrease in the Ashworth scale score and an in-
crease in the range of motion) were statistically signifi-
cant compared to the placebo group and were maintained 
for at least 2 months after treatment. 
 Chronic Skin Ulcers 
 The use of ESWT in chronic skin lesions stems from 
the observation of a ‘collateral’ trophic effect during the 
treatment of bone non-union in the presence of an ulcer 
 [43] . The subsequent development of defocused technol-
ogy allowed the extension of the treatment to various 
chronic vascular lesions of different aetiologies, with evi-
dence of complete healing or at least a reduction in the 
size of the area of the lesion. Wound healing after ESWT 
is characterized by the production of granulation tissue 
with the arrival of leucocytes, which is closely correlated 
to an increase in vascular density and local blood flow. 
This effect has been shown with laser Doppler imaging in 
the case of ESWT for the treatment of burns  [44, 45] .
 The increase in capillary density of the treated tissues 
after a single dose of defocused SW has been observed in 
various experimental studies. Human microendothelial 
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cells (HMEC-1) expanded on a three-dimensional matrix 
show an increase in capillary connections at 12 h after 
treatment, together with an early (3 h) downregulation of 
proapoptotic genes  [46] . Stojadinovic et al.  [47] reported 
an increase in vascular flow at 4 and 7 days after treatment 
of ischaemic skin and a significant upregulation of pro-
angiogenic genes after 6 h. This improvement in the via-
bility of the ischaemic tissue subjected to SW has been 
correlated to an increase in capillary density, supported 
by increased expression of von Willebrand factor and 
smooth muscle actin protein. In ischaemic tissues, the 
vascular effects of SW seem to be independent of the time 
of their application, whether it be before ischaemia, im-
mediately after ischaemia, or 24 h after ischaemia  [48] . 
Furthermore, the protective mechanism of SW has been 
postulated as a function of the presurgical prophylaxis. 
The experience of Dumfarth et al.  [49] shows an enhanced 
capacity for healing of the surgical wound at the donor 
site of the transplant vein used for revascularization of the 
myocardium, as shown by the better trend of the ASEPSIS 
score. They reported a statistically significant difference 
in the incidence of complications between patients treat-
ed with SW and controls (4 vs. 22%, p = 0.015).
 Other clinical applications of ESWT for the treatment 
of vascular skin lesions include chronic posttraumatic, 
venous and diabetic ulcers which have been unresponsive 
to other conservative treatments  [50] . Chronic diabetic 
foot ulcers in particular require a multidisciplinary ap-
proach, as the results of surgical treatment are often un-
satisfactory. Adjunctive therapies have been developed 
for treating ulcers, and various studies have reported the 
beneficial effect of hyperbaric oxygen therapy. However, 
Wang et al.  [51] showed that ESWT is more effective than 
hyperbaric oxygen therapy in improving the blood flow 
perfusion rate and cell activity, with an associated de-
crease in apoptosis.
 Bone Vascular Diseases  
 ESWT has been shown to be effective in the early stag-
es of femoral head osteonecrosis by reducing the exten-
sion of the necrotic area, avoiding further bone collapse. 
The effectiveness of the treatment has also been shown 
compared to core decompression and bone grafting. The 
treatment may delay the requirement for total hip arthro-
plasty and, in addition, it can cause a significant decrease 
in bone marrow oedema patterns and associated pain  [52, 
53] . SW improve new vessel in-growth and blood supply. 
Furthermore, they induce a significant increase in the pro-
duction of osteocalcin and transforming GF (TGF-β 1 ) and 
stimulate osteoblasts and periosteal cells and the osteo-
genic differentiation of mesenchymal stem cells. These ef-
fects arise via the activation of free radicals and oxygen-
reactive species such as NO, and involve the activation of 
signal proteins (ERK) and transcriptional factors (core 
binding factors or CBFs)  [11, 54] . In addition to the regen-
erative effect, recent hypotheses emphasize the direct role 
of SW in bone modelling and remodelling. The experience 
of Tamma et al.  [16] in murine osteoblasts highlights the 
effect on the RANKL/OPG ratio, and the authors theorize 
a potential inhibition of osteoclastogenesis. Otherwise, in 
vivo experiments show that SW treatment affects the dy-
namics of the bone architecture, with potential applica-
tions in conditions characterized by altered metabolism 
such as osteopenia and osteoporosis  [55] . Finally, prelim-
inary clinical experiences report the effectiveness of ESWT 
in the early stages of Kienböck disease  [56] .
 Myocardial Ischaemia 
 ESWT is currently one of the new alternative treat-
ments for cardiac ischaemia, due to the above-mentioned 
neoangiogenic effects of low-energy SW. Research into 
the specific effect of SW on cardiac primitive cells, iso-
lated from normal and explanted pathologic postisch-
aemic human hearts, reveals a positive influence on both 
the proliferation and the differentiation of cardiomyo-
cytes, smooth muscle and endothelial cell precursors  [57] . 
In animal models of chronic myocardial ischaemia, the 
application of SW has resulted in the recovery of left ven-
tricular ejection fraction and an improvement in regional 
myocardial blood flow associated with an upregulation of 
VEGF expression  [58, 59] . An increase in vascular den-
sity 6 and 14 weeks after SW treatment was described in 
a rodent model of ischaemic heart failure  [59] .
 Building on the positive results of the in vitro research, 
clinical studies are starting to be published. A patient co-
hort treated with low-energy SW showed an improve-
ment of their left ventricle ejection fraction  [60] . Al-
though more clinical studies are required to validate the 
efficacy of ESWT in cardiac ischaemic conditions in com-
parison to other more invasive treatments, it seems to be 
safe and without adverse effects.
 Dental Conditions 
 Bone resorption is typical in periodontal inflamma-
tion. Recent in vivo experience has demonstrated that SW 
could enhance alveolar bone regeneration in infected gin-
givalis tissue  [61] . The use of unfocused SW gradually 
normalizes the volume of healthy bone at 1–2 weeks after 
a single treatment, and the anti-inflammatory effect con-
tinues for at least 6 weeks. It has also been observed that 
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certain species of oral bacteria react to treatment with 
SW; the response is dependent upon the energy level used 
and the species of the pathogen. Different energy levels 
can cause the disaggregation of Gram-positive and Gram-
negative bacteria and some pathogens that are associated 
with serious oral and systemic infections like  Streptococ-
cus mutans and  Porphyromonas gingivalis  [62] . When 
considered together, these data seem to suggest potential 
new therapeutic approaches for the treatment of dental 
disease.
 Conclusions 
 In conclusion, ESWT is a modern, non-invasive thera-
peutic tool which is effective, safe and advantageous. 
ESWT may replace surgery in several orthopaedic pathol-
ogies with at least the same results, but without its draw-
backs. The potential for translational research and devel-
opment of ESWT technology is remarkable and probably 
still undisclosed. 
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